Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes ...
Vertex has enacted or continued several key launches in 2025. These include its new once-daily triple-combination therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback